-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Initiates Coverage On Eikon Therapeutics with Buy Rating, Announces Price Target of $23

Benzinga·10/16/2026 10:11:02
Listen to the news
HC Wainwright & Co. analyst Sara Nik initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Buy rating and announces Price Target of $23.